RUNX3 and non-small cell lung carcinoma: Another study found that RUNX3 expression is lost in non-small cell lung cancer (NSCLC), leading to the upregulation of CCL5 and CCL19 in NSCLC cells, which was associated with tumor-associated bone destruction [82].